Affiliation:
1. School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau 999078, China
2. Pharmacology Laboratory of Prevention and Treatment of High Incidence of Disease, Guilin Medical University, Guilin 541199, China
Abstract
Nasopharyngeal carcinoma (NPC) is closely linked to Epstein–Barr virus (EBV) infection. Curcumae Rhizoma, a traditional Chinese herb, has shown antitumor effects, primarily through its component curcumol (Cur), which has been shown to reduce NPC cell invasion and migration by targeting nucleolin (NCL) and Epstein–Barr Virus Nuclear Antigen 1 (EBNA1). We constructed an EBV-positive NPC cell model using C666-1 cells and performed transcriptomics studies after treatment with curcumol, which revealed a significant enrichment of ubiquitin-mediated proteolysis, the PI3K-AKT and mTOR signaling pathways, cell cycle and apoptosis involved in tumor invasion and migration. To investigate the importance of NCL and EBNA1 in curcumol-resistant EBV-positive NPC, we performed a multi-omics study using short hairpin NCL (shNCL) and shEBNA1 EBV-positive NPC cells, and the proteomics results showed enrichment in complement and coagulation cascades and ubiquitin-mediated proteolysis signaling pathways. Here, we focused on ubiquitin-conjugating enzyme E2C (UBE2C), which plays an important role in the ubiquitin-mediated proteolysis signaling pathway. In addition, metabolomics revealed that UBE2C is highly associated with 4-Aminobutanoic acid (GABA). In vitro studies further validated the function of the key targets, suggesting that UBE2C plays an important role in NCL and EBNA1-mediated curcumol resistance to nasopharyngeal carcinoma invasion and metastasis.
Funder
Natural Science Foundation of Guangxi Province
Project Guangxi Special Fund Project for Innovation-Driven Development
National Natural Science Foundation of China
Reference36 articles.
1. Nasopharyngeal carcinoma;Chen;Lancet,2019
2. EBV infection-induced GPX4 promotes chemoresistance and tumor progression in nasopharyngeal carcinoma;Yuan;Cell Death Differ.,2022
3. Li, W., Duan, X., Chen, X., Zhan, M., Peng, H., Meng, Y., Li, X., Li, X.Y., Pang, G., and Dou, X. (2022). Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma. Front. Immunol., 13.
4. Epstein-Barr virus in the pathogenesis of NPC;Semin. Cancer Biol.,2002
5. Genetic and epigenetic changes in nasopharyngeal carcinoma;Lo;Semin. Cancer Biol.,2002